Identification of Candidate Inhibitors to SARS-CoV-2’s Enzymes and Potential Disruptors of Its Structural Proteins’ Interactions Authors: Ali Mohammadian, Mahdieh Jadaliha, Aylar Imanpour, Hamed Pourvali Moghadam, AmirHossein Jahangir Published: 2025 ABSTRACT Background:Many studies have assessed the possible inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, experiences like that from human immunodeficiency virus have taught us that a multidrug approach will reduce the chance of viral resistance.Materials and Methods:Here, we screened 2371 Food and Drug Administration-approved drugs for possible inhibition of nonstructural proteins of SARS-CoV-2 and expanded the work to include ligands that might interfere with the roles of structural proteins. Three different algorithms were used and suggested hits obtained using qVina were verified using Autodock Vina and leDock software.Results:Our results suggest direct-acting antivirals against hepatitis C might be efficient against SARS-CoV-2.Conclusions:Drug repurposing is a promising approach for the rapid identification of potential treatments for emerging diseases such as coronavirus disease. INTRODUCTION The recent coronavirus disease (COVID-19) cases have surpassed 510 million and claimed more than 18 million lives as of 2021.[1] Despite many vaccines, only ~17% in low-income countries have received a first dose.[2] On the other hand, remdesivir stands as the sole medication approved by the Food and Drug Administration (FDA) for COVID-19 treatment.[3] At a regular pace, the approval process for drugs takes 10 to 15 years and costs around 1 billion US dollars. In the emergency of the COVID-19 pandemic, this procedure should be expedited and the hunger for computational assistance is tangible more than ever to reduce the time, labor, and cost. In this direction, drug repurposing could provide us with valuable information on existing drugs and their potential in combating emerging diseases. For such candidates, the existing therapeutic index and records on safety and toxicity could pave the way through accelerated human clinical trials in general and in COVID-19 patients in especial. Virtual screening, the docking of a large number of ligands against a protein, can be used to find putative protein binders. The docking technique estimates the energy of ligand–protein binding.[456] A novel member of the Coronaviridae family, SARS-CoV-2, is the infectious agent responsible for the global pandemic known as COVID-19, and none of the existing approved drugs have been initially designed to target the SARS-CoV-2 proteins. However, detailed information on SARS-CoV-2 protein sequences and structures is available. SARS-CoV-2 genome encodes structural proteins including nucleocapsid (N) protein, membrane (M) glycoprotein, spike (S) glycoprotein, small envelope (E) glycoprotein, and 16 nonstructural proteins (NSPs).[7] Computational approaches such as molecular docking analyses could help predict previously approved ligands interactions with SARS-CoV-2 proteins. In this study, we selected 2454 FDA-approved small-molecule drugs as ligands and viral/host proteins involved in the virus replication cycle as targets.[6] Briefly, virtual screening was performed after preparation of ligands and proteins. We tested the binding potential of the ligand drugs and different SARS-CoV-2 proteins. We evaluated the binding affinities with two different algorithms including qVina and LeDock[58] and selected the most promising candidates. The results were initially analyzed with qVina, and anti-HCV drugs were manually selected for further analysis. To confirm the docking results with qVina software, the filtered drugs were also examined by LeDock docking software. Drugs that were approved by both algorithms were tested with the prodigy server as well. MATERIALS AND METHODS Ligands All currently FDA-approved drugs (N = 2454) were downloaded from DrugBank.[9] The 2D structures were converted to 3D structures using Python Rdkit module,[10] and in case of failure, Marvin suite.[11] Generated 3D structures were minimized for 100,000 steps using UFF global force field in Openbabel.[12] pdbqt format files for docking using Autodock were created using the python script provided by the latest version of MglTools, 2.1.[13] SDF files for docking with LeDock were converted directly from pdbqt files using Openbabel. Proteins Next, structural files of SARS-CoV-2 proteins were fetched from the RCSB database.[14] In case of incomplete structures, missing residues were modeled using Modeller 9.24 and the top models according to zDOPE score and GA341 score were chosen.[15] The models were converted to the pdbqt format required for qVina using PyRx. LeDock-protein was used to create input files for LeDock-go. In case of the presence of a ligand in the protein file, the box around the ligand encompassing the binding pocket was defined as a binding box. In case of interaction of two proteins, the place where the virus and the host protein or two viral proteins interact was selected with the minimal box so as to prevent the effects of post-transcriptional modification of viral proteins, for example, glycosylation. Virtual screening Virtual screening was performed using qVina on 12 viral proteins and two human proteins. The ligands with binding affinity less than -8 kCal/mol were selected for further filtering and verification using LeDock. As we found all screened proteins bind drugs with primary targets outside of the human body, these drugs were used to verify using LeDock. These drugs are expected to have less side effects, pharmacodynamically. Proteins were visualized using Chimera. Protein–ligand interactions were calculated and visualized using Discovery studio 2020. RESULTS Ligand and protein preparation A total of 2454 approved drugs in 2D SDF format were obtained from DrugBank. We found that Openbabel 3.0.0 failed to produce 3D representation of molecules using the required flags: --gen3d –best -3d. However, Rdkit python module could generate 3D in most situations. The few remaining 2D sdfs were fed to Marvine suite to obtain 3D sdfs. Out of 2454 downloaded molecules, 2371 were ready for virtual screening. We received structural and nonstructural either SARS-CoV-2 [Figure 1] or related human proteins in pdb format. Incomplete protein structures were modeled using MODELLER 9.24, and 12 SARS-CoV-2 proteins and two human proteins with the lowest zDOPE score and the highest GA341 score were selected for virtual screening [Table 1]. The missing parts of proteins are listed in Table 1. Eventually, the proteins were converted to the pdbqt format for further analyses. The viral proteins used in this study, along with their RCSB codes Table 1Modeling missing residues of proteins using MODELLERViralStructuralPDB codes Screen targets in boldMissing residues (3 in a row)E - Envelope small membrane protein (75 aa)5×29, 2mm4A: B: C: D: E:-15 to+7Spike glycoprotein, mediates binding to ACE2 (1273 aa)6lzg, 6m0j, 6m17, 6vw1, 6vsb, 6lvn, 6lxt, 6w41,6vxxB: 319-332, B: 528-547N - nucleocapsid phosphoprotein, binds to RNA genome (419 aa)6vyo, 6m3mA: B: C: D: 46-49Non-structuralNSP1 - mediates RNA replication and processing suppresses host antiviral response (180 aa)2hsx, 2gdtnoneNSP3 - involved with NSP4 and NSP6 in viral replication (1945 aa)6w9c, 6w02,6vxs, 6w6yB: 1-3 B: 224-228 B: 315-317 c: 1-3NSP4 - involved with NSP3 and NSP6 in viral replication (500 aa)3gzf, 3vc8, 3vcbB: 50-52 C: 92-95 d: 92-95 e: 50-55 e: 90:95NSP56lu7noneNSP7 - complex with NSP8 is part of RNA polymerase (83 aa)6m71A: 1-30_51-68_103-111_896-905_920-942_ C: 72-83_D: 1-83_D: 123-128, 133-198, B: 1-77, 192-168NSP8 - complex with NSP7 is part of RNA polymerase (198 aa)6m71see aboveNSP9 - ssRNA binding (113 aa)6w4bA:-2-5NSP10 - essential for NSP16 methyltransferase activity (138 aa)6w75, 6w4h, 6w61A: 6796-6799, B: 4251-4270, C: 6934-6938, D: 4251-4270, D: 4386-4392NSP12 - RNA polymerase (931 aa)6m71see aboveNSP13 - helicasetriphosphatase (601 aa)5wwp, 6vxs, 6jytB: 186-191, A: 147-230NSP14-3’-5’ exonuclease (527 aa)5c8s, 5nfy, 5c8u, 5c84A: 132-139, B: 454-464, C: 132-139, D: 454-464NSP15 - uridine-specific endoribonuclease (346 aa)6vww, 6w01A:-23_-1, B:-23_-1NSP16 - RNA-cap methyltransferase (297 aa)6w75, 6w4hsee aboveHumanFurin (794aa)6hzbnone Modeling missing residues of proteins using MODELLER QVina results Qvina results are shown in Table 2. A striking result was the presence of hepatitis C drugs in qVina top list for almost all viral proteins. As antivirals have their primary target outside of the body, they are preferable to other top ligands, especially those that affect COVID-19-related symptoms/mechanisms. It should be noted that vina algorithm did not lead to these hits when tested on other proteins such as 4pd3 human nonskeletal mysosin II. Table 2Top ligands as obtained by qVina and leDockPDBqVinaLeDock LigandAffinityLigandScore2hsxLedipasvir-9.3Trypan blue free acid-10.53862hsxTrypan blue free acid-8.8Ledipasvir-9.55692hsxAlectinib-8.3Trypan blue free acid-8.90212hsxPlerixafor-8.1Ledipasvir-8.54653gfzVancomycin-10.5Velpatasvir-10.51823gfzAmphotericin B-10.4Elbasvir-10.16233gfzLinaclotide-10.1Velpatasvir-9.87663gfzNilotinib-10.1Ledipasvir-9.53895c8sErgotamine-10Velpatasvir-8.95365c8sLomitapide-9.9Paritaprevir-8.42175c8sDihydro-alpha-ergocryptine-9.7Elbasvir-8.39275c8sDihydroergotamine-9.5Daclatasvir-8.30035×28Conivaptan-11.9Elbasvir-8.34785×28Dactinomycin-11.6Ledipasvir-8.02245×28Conivaptan-11.6Elbasvir-8.00555×28Paritaprevir-11.2Ledipasvir-7.72956m17Conivaptan-8.6Velpatasvir-8.65016m17Venetoclax-8.5Elbasvir-8.37246m17Ergotamine-8.5Ledipasvir-7.75526m17Dactinomycin-8.1Velpatasvir-7.52126w61Dutasteride-8.7Elbasvir-8.09416w61Conivaptan-8.6Velpatasvir-7.90976w61Dihydroergocristine-8.6Daclatasvir-7.85386w61Venetoclax-8.6Paritaprevir-7.75wwpDactinomycin-12NANA5wwpPibrentasvir-11.6NANA5wwpPlicamycin-11.5NANA5wwpDeslanoside-11.1NANA6w9cDihydroergotamine-11.4Ledipasvir-10.09276w9cErgotamine-11.3Daclatasvir-9.44786w9cTemoporfin-11.3Ledipasvir-9.12976w9cTrabectedin-11.1Velpatasvir-9.00646hzbDactinomycin-10.4Elbasvir-9.23886hzbQuinupristin-10.2Paritaprevir-9.18626hzbEribulin-9.8Ledipasvir-9.00226hzbImatinib-9.8Paritaprevir-8.97296lu7Hydroxocobalamin-12.7Ledipasvir-10.20946lu7Methylcobalamin-11.3Elbasvir-9.69986lu7Goserelin-10.8Velpatasvir-8.88786lu7Cobamamide-10.1Daclatasvir-8.596lzg-cErgotamine-9.5Ledipasvir-8.63226lzg-cConivaptan-9.2Elbasvir-8.6276lzg-cDihydroergotamine-9.1Ledipasvir-8.57466lzg-cLedipasvir-9Elbasvir-7.676lzg-vIrinotecan-9.5Ioxaglic acid-9.79316lzg-vDihydroxyergotamine-9.2Ceftolozane-9.49296lzg-vErgotamine-9.2Ceftriaxone-9.25356lzg-vDactinomycin-9.1Ceftaroline fosamil-9.15756m71Rolapitant-11.1NANA6m71Lumacaftor-10.6NANA6m71Simeprevir-10.5NANA6m71Dactinomycin-10.4NANA6vwwTannic acid-12.9Paritaprevir-11.09186vwwPlicamycin-11.9Elbasvir-10.75076vwwVenetoclax-11.8Paritaprevir-10.44856vwwGlycyrrhizic acid-11.8Velpatasvir-10.26536yoDactinomycin-10.7Elbasvir-8.31176yoTemoporfin-10.4Elbasvir-8.25916yoGlecaprevir-9.6Paritaprevir-8.2236yoErgotamine-9.6Ledipasvir-8.16786w75NANAElbasvir-8.74736w75NANAElbasvir-8.50956w75NANAElbasvir-8.3996w75NANAVelpatasvir-8.32876w75NANAElbasvir-7.9337 Top ligands as obtained by qVina and leDock Vina and leDock results The interaction of individual ligands with individual viral proteins was initially investigated by docking with qVina software under a Linux environment. We tested the interaction of the 2317 ligands and 14 proteins and identified the ten best results for each protein and drug. We selected the best results and manually picked the most promising ligand–protein pairs. Then we confirmed the candidates with autodock vina and LeDock as a second independent method. Our preliminary data demonstrated that in addition to drugs such as ergotamine and dactinomycine, which strongly interact with a wide range of viral proteins, hepatitis C-related drugs are also among superior ligands. SARS-CoV-2 and HCV are both viruses with positive-stranded RNA genome and have more similar infectious cycles compared to DNA viruses or RT-RNA viruses. For example, it is not surprising that a recent study illustrated that HCV protease shows one of the highest 3D structure similarities to SARS-CoV-2 protease among seven viral and mammalian proteases.[16] On the other hand, antivirals such as anti-HCV drugs have some advantages over nonantiviral drugs such as anticoagulants as the second could worsen the disease by interfering with body physiology and metabolism. Altogether, we considered anti-HCV drugs with strong interactions for verification with LeDock. None of the top ligands were among top ligands interacting with human nonskeletal myosin using Vina. LeDock results Docking analysis with LeDock revealed that anti-HCV drugs such as elbasvir, ledipasvir, velpatasvir, glecaprevir, paritaprevir, simeprevir, pibrentasvir, and daclatasvir are promising drug repositioning candidates for COVID-19 therapy [Table 3]. Several of these ligands could potentially interact with SARS-CoV-2 protein targets with an estimated free binding energy lower than -8.0 kcal/mol. The top drugs’ interaction with humans and SARS-CoV-2 proteins are presented in Figure 2. Top 30 mechanisms of the FDA-approved drugs used for screening Table 3Results of proposed drugs for different proteins. Possibly synergistic drugs are demonstrated with an asteriskProteinRoleProposed drugsViralStructural 5×29 (Surya, Li et al. 2018)Envelope small membrane protein---- 6lzg-(Viral part) (Wang, Zhang et al. 2020)Mediates binding to ACE2Velpatasvir, Elbasvir, Ceftolozane, Lomitapide 6vyo (Chang, Michalska et al. 2020)Binds to RNA genomeGlecaprevir, Paritaprevir, ElbasvirNon-structural 2hsx (Almeida, Johnson et al. 2007)RNA replication, suppression of host antiviral responseLedipasvir 3gzf (Manolaridis, Wojdyla et al. 2009)Viral replicationLinaclotide, Elbasvir 6lu7 (Jin, Du et al. 2020)Main proteaseLedipasvir, Elbasvir 6m71 (Gao, Yan et al. 2020)RNA polymeraseSimeprevirLedipasvir 6w75 (Rosas-Lemus, Minasov et al. 2020)Methyltransferase activityElbasvir, Velpatasvir 5wwp (Hao, Wojdyla et al. 2017)HelicasetriphosphataseElbasvirPibrentasvir 6vww (Osipiuk, Jedrzejczak et al. 2020)EndoribonucleaseParitaprevir, imeprevir, Ledipasvir 6w9c (Osipiuk, Jedrzejczak et al. 2020)Papain-like proteaseLedipasvir, Velpatasvir 5c8s (Ma, Wu et al. 2015)Viral replication and transcriptionVelpatasvir, Paritaprevir, Elbasvir, Daclatasvir 6w61 (Rosas-Lemus, Minasov et al. 2020)Methyltransferase activity Human Structural 6lzg-(Human cellular part) (Wang, Zhang et al. 2020)ACE2, mediates binding to virusLedipasvir, ElbasvirNon-structural 6hzb (Van Lam van, Ivanova et al. 2019)FurinQuinupristin Results of proposed drugs for different proteins. Possibly synergistic drugs are demonstrated with an asterisk Possible synergism As repositioned drugs have not been designed for the emerging proteins, they are potentially weak target binders, and higher concentrations might be needed to achieve the desired inhibitory effect. Despite using drugs with targets outside of the body, which might enable a wider therapeutic window, we also looked for drugs binding to nonoverlapping parts of each protein. The results are listed in Table 4 and depicted in Figures 3 and 4. Top drugs’ (green) interaction with SARS-CoV-2 and human proteins (red). The inteacting surface of protein is shown in blue. The interacting residues are also demonstrated for each protein. The respective pdb code is given for each protein Possible synergism between drugs. (a) 2hsx + partitaprevir + ledipasvir. (b) 5wwp38 + elbasvir* pibrentasvir Table 4Drugs with possible synergismProteinRoleProposed drugsViralNon-structural 2hsx (Almeida, Johnson et al. 2007)RNA replication, suppression of host antiviral responseLedipasvir * LumacaftorElbasvir*ParitaprevirTrypan blue free acid* Lumacaftor 5wwp (Hao, Wojdyla et al. 2017)HelicasetriphosphataseElbasvir* Pibrentasvir Drugs with possible synergism DISCUSSION The latest coronavirus breakout originated from bats spilled over into humans in late 2019 and created a truly unprecedented crisis for the modern medicine. Many efforts have been put toward improving diagnosis, developing prophylactic vaccines, screening for efficient treatments, and implementing social distancing strategies across the globe. The disease is with no or mild symptoms in 80% of the infected population, although viral shedding and transmission to contact people still occur. Even in the case of symptomatic patients, the virus shedding starts in the presymptomatic phase and well ahead of the symptom onset.[17] Social distancing policies challenged the world economy dramatically. In yet-undrugged transmissible viral diseases, the world is in hunger of resuming the normal lifestyle by finding alternative strategies to break the virus transmission chain rather than social distancing. One such alternative strategy could be frequent testing to identify carrier individuals on time and to specifically isolate the carries of the infectious virus rather than every suspected person. Developing prompt, cheap, and easy tests is crucial to facilitate such regular testing. Currently, RT-qPCR is mainly used to diagnose the viral presence in patients, and antibody-based serologic tests are performed to evaluate the presence of humoral immune response upon recovery.[18] Current diagnosis costs more than $100, and a few hours to a few days are required to get the results. Furthermore, the diagnosis usually happens after onset of symptoms, which is too late for isolation. The saliva-based lateral flow at-home tests are proposed to ameliorate the diagnosis, but we are still far away from such cheap, easy, and rapid detection. The other arm of fight against COVID-19 is vaccine development. Frontier vaccine companies such as Moderna, Astrazeneca/Oxford, Sinovac, and BionTech have successfully passed safety and dosing tests, and their vaccines are approved for humans. However, COVID-19 situation is emerging and rapidly evolving and little is yet known about its pathology and immune response. Long-term immunity and effectiveness of vaccines are still under question, and reinfection possibility is not ruled out. Reinfection after 3 months of initial infection is assumed likely according to US Centers of Disease Control and Prevention (CDC).[19] Further vaccination boosts would be required to confer longer immunity and would increase manufacturing efforts. The concerns and limitations about social distancing, diagnosis, and vaccination reinforce the urgent need for the development of effective treatments to cease this crisis. It is sensible to survey pre-existing approved medications which have passed the safety qualifications and are known to be well tolerated by humans. The mechanism of function of BSAs differs, and several BSAs such as remdesivir, favipiravir, lopinavir, and ritonavir are in clinical trials or approved for limited use in COVID-19 therapy.[20] In this study, we examined the binding of more than 2000 FDA-approved drugs to SARS-CoV-2 proteins by two different computational methods of qVina and LeDock. Here, we found that drugs such as elbasvir, ledipasvir, velpatasvir, glecaprevir, paritaprevir, simeprevir, pibrentasvir, and daclatasvir could be used individually or in combinations to fight against the COVID-19. Least is known about the efficacy of these drugs on SARS-CoV-2 inhibition, but the safety and efficacy of these medications are well documented in case of HCV proteins. In previous computational target-based drug repurposing investigation, elbasvir was predicted to bind to proteins necessary for viral replication of SARS-CoV-2.[2122] Another study indicated that antivirals ledipasvir and velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache.[23] The computational analysis proposed that paritaprevir is an excellent lead candidate and could become a potential therapeutic drug against SARS-CoV-2.[24] Using computational methods identified that glecaprevir is an inhibitor of SARS-CoV-2.[25] The previous results indicate that simeprevir might be a helpful treatment option for COVID-19.[26] While these results suggest antiviral efficacy, follow-up clinical trials are required to validate these drugs as a potential therapy against SARS-CoV-2. Among all these drugs, clinical trials are underway for ledipasvir (NCT04530422) and daclatasvir (NCT04443725) to evaluate the efficacy and safety of anti-HCV drugs in the treatment of COVID-19. The previous results indicated that when daclatasvir was used as a medication for COVID-19 outpatients, it significantly decreased the number of cases with dyspnea and fatigue within 1 month.[27] Both antiviral drug therapy and drug repositioning possess intrinsic inadequacies. Owing to error-prone viral nucleic acid polymerases, new viral variants are produced, some of which would evade either vaccination or direct-acting antiviral drugs. A possible strategy to overcome this viral adaption is the cotherapy of patients using multiple drugs, a procedure proved successful and in common use for HIV treatment.[28] Another caveat to drug repurposing against is inherent to drug repositioning, that is, due to original design of drugs for other protein targets; for example, direct acting antivirals found in this study are not designed for the most similar viral species to COVID-19. Here, we did our best to find drugs that target different proteins in the virus, unlike other studies. In addition to heightening drug concentration, one would like to use synergism between drugs. Here, we also reported drug combinations that do not occupy the same area in the active site of the viral proteins. Further molecular dynamic simulation is required to confirm our results. Algorithms do not replicate top ligands, and we suggest use of more than a single docking programs and feed the union of top ligands to molecular dynamics study. Despite the potential of the proposed drugs, there are possible caveats that should be considered. For example, drugs such as elbasvir, ledipasvir, velpatasvir, and paritaprevir could bind to multiple structural and nonstructural SARS-CoV-2 proteins. Correlating a ligand to various targets could be due to the algorithm bias. To overcome the bias, we confirmed the bindings with different algorithms. Binding to different targets reduces the effective concentration of the drug that interacts with each target protein and should be concerned in dose optimization. In addition, the position where the ligand and the target protein interact could determine the function. In general, the ligand drugs could function in orthosteric or allosteric modes. Orthosteric drugs bind to active sites of the target protein, and their mechanism is based on the competition with endogenous substrates and thereby inhibition. However, allosteric drugs bind to sites different from active sites and lead to structural changes in protein. In general, allosteric sites are less conserved than active sites. Therefore, allosteric ligands raise less concern about polypharmacology compared to orthosteric ligands. Polypharmacology is defined as single-drug interactions with multiple targets, which could happen more often when the targets site is conserved between distinct proteins. Thus, it is valuable to know where each drug candidate binds to SARS-CoV-2 proteins. Molecular dynamic analysis could be performed to achieve this goal. On the other hand, binding to the binding pocket (not the protein cavity or the joint surface of the two proteins) is also likely to make the protein more active. Thus, we used inhibited protein structures for docking and top ligands stabilize the inhibited structure and we expect protein inhibition. We suggest the molecular dynamics method could be used to provide more accurate information but required more time and effort. Next, Hepatitis C drugs take long times to take effect. In addition, drugs are suggested to lower the virus titer and reduced mortality will be a side effect of drugs. Thus, the drug should be tested on those who have recently acquired the virus, which is contrary to the rational policy of testing the drug on critically ill patients. Therefore, it is strongly suggested that if drugs are used on these patients, the process of changing the virus titer in them should be monitored and compared with the control group, and if the titer reduction mechanism is approved, the drugs should be tested for patients with nonsevere conditions. Structural proteins usually bind other proteins or macromolecules. However, PPI (protein–protein interaction) surfaces are not usually druggable in the sense of traditional small molecules. An inevitable characteristic of proteins is their flexibility. This is not yet considered as on-target repurposing as the original mechanism of the drugs is unknown. Many current medications interact with multiple protein targets, some of which are already identified. Recent research has examined the scope of this multitarget interaction by analyzing known drug–target relationships. Scientists have developed a network mapping proteins that share chemical binders, illustrating human pharmacological interactions. In one study involving 276,122 active compounds, over a third affected more than one target. Another study, combining data from seven drug–target interaction databases, found that drugs typically interacted with six different targets on average. However, for off-target repurposing to be viable, the drug must not only act on a secondary target but also do so within a therapeutically appropriate dose range. Consequently, off-target repurposing occurs less frequently than on-target repurposing. Interestingly, a study[29] suggests effectiveness of drug repurposing for COVID-19. We suggest the successful application of virtual screening may be extended to different cancer and other diseases. While different treatment modalities, for example, using small molecules, immunological, or even electromagnetic treatment, are being investigated on cancer patients,[30313233] the relatively well-studied systems biology of cancer[3435] or other diseases[3637] can be well harnessed by the addition of drug repurposing studies through virtual screening. CONCLUSION Drug repurposing is a promising approach for the rapid identification of potential treatments for emerging diseases such as COVID-19. By leveraging existing drugs that have already been approved for other indications, drug repurposing can significantly shorten the drug discovery process as the safety and pharmacokinetic profiles of these drugs have already been established. In the case of SARS-CoV-2, drug repurposing has shown promise in identifying several repositioned drugs that could potentially be effective against the virus. These drugs have the potential to provide immediate relief to COVID-19 patients while more specific treatments are being developed. Conflicts of interest There are no conflicts of interest.